Fabian Kurth: Celebrating Teamwork and Cardiovascular Heritage at ESC Congress 2026
Fabian Kurth, Business Unit Director – Innovative Medicines (CH-AT) at Bristol Myers Squibb, shared a post on LinkedIn:
“The best part of ESC Congress 2026? Experiencing it with this team.
Our one chat team from Switzerland and Austria, together in Munich – engaging with the cardiology community and proud to be part of a genuine heritage story in cardiovascular care!
For over a decade, the anticoagulant class of DOACs has changed outcomes for millions of patients in stroke prevention and thrombosis.
Today, more targeted therapies are emerging in the cardiomyopathy space that are really making a difference for patients. And the science around a new mode of action targeting Factor XI is evolving rapidly – one of the most exciting frontiers in the field.
Past, present, and future of cardiovascular innovation – all visible in one place, and our team right in the middle of it.
Thank you, team, for your energy, expertise and passion.
It’s a privilege to work alongside you.”
Stay updated with Hemostasis Today.
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session
-
Aug 30, 2026, 17:02David McGlasson: A 2020 Article Reaches 8,000 Reads
-
Aug 30, 2026, 16:18Tushar Namdeo: Platelets in Different Diseases
-
Aug 30, 2026, 16:16Fatima Zafar: Anaemia – Why This “Common” Condition Should Never Be Ignored
-
Aug 30, 2026, 16:13Umeshkumar C.: Evaluating Scoring Systems and Biomarkers for DIC in Critically Ill Patients